October 20, 2009
Nijmegen Centre for Molecular Life Sciences Applies Genomatix NextGen Sequencing Data Analysis
Henk Stunnenberg's lab experiences feed back into Genomatix' further developments.
Munich, Germany, Oct.20, 2009 - Genomatix Software, the leading provider of solutions for the comprehensive analysis of Next Generation Sequencing (NGS) data, announced today that the Nijmegen Centre for Molecular Life Sciences (NCMLS) installed a Genomatix Genome Analyzer (GGA) at Henk Stunnenberg's lab. Henk Stunnenberg, a pioneer in transcription factor analysis and epigenetic research, is full professor, head of the Department of Molecular Biology, and a member of EMBO.
The Genomatix Genome Analyzer delivers a complete and integrated solution for the downstream analysis of NGS data. Rich biological background knowledge, integrated in databases and comprehensive software tools, enable a molecular level understanding of the biology being studied within a few hours.
"The GGA has the advantage of incorporating all of the renowned software and data content Genomatix has built over the past 11 years, and putting an excellent NGS overlay on it all" says Prof. Dr. Henk Stunnenberg. "This allows us to drill down into the biology of our systems in an easy to use workflow environment with all their terrific science in the background".
Martin Seifert, Chief Executive for Marketing and Consulting at Genomatix, says: "I am very proud that Dr. Stunnenberg has chosen our system. With our combined hardware/software approach, we are able to get the most out of data from Next Generation Sequencing experiments in surprisingly short time. Especially in the field of ChIP-Seq and RNA sequencing, thus shortening the time to publication significantly. For Dr. Stunnenberg's group, with its many brilliant scientists, our integrated systems are greatly facilitating their data analysis process. We are really pleased that the response from the group is very positive, and their feedback will contribute substantially in helping to define the direction of further developments of our technology at Genomatix".
The Nijmegen Centre for Molecular Life Sciences (NCMLS) is a leading multidisciplinary research school within the domain of molecular mechanisms of disease and particularly in the fields of molecular medicine, cell biology and translational research. The research is focused in keeping with the mission towards understanding the cellular basis of disease. Henk Stunnenberg's research interest is in the unraveling of the molecular basis of cell behaviour emanating from the genetic and epigenetic code contained in the nucleus in the context of health and disease
Genomatix Software GmbH is a computational biology company headquartered in Munich, Germany with a seat of business in Ann Arbor, MI, U.S.A. Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. Over a decade of developments in computational and systems biology has put Genomatix into position to have a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 180 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases.
More information is available from http://www.genomatix.de or http://www.genomatix-software.com.
April 3, 2009
UMICH Center for Computational Medicine and Bioinformatics installs Genomatix Genome Analyzer
Munich (Germany), Ann Arbor, MI (USA) - April 3, 2009 - Genomatix Software, a leading provider of complete solutions for the analysis of Next Generation Sequencing (NGS) data, announced today that the CCDU Bioinformatics Core of the Center for Computational Medicine and Biology at the University of Michigan installed a Genomatix Genome Analyzer (GGA) at its labs in Ann Arbor, MI. The GGA is a purpose built high performance computer pre-configured with terabytes of proprietary database and software technology combined to provide a turnkey solution for the analysis of NGS data. It represent a complete, integrated analysis solution for the downstream analysis of NGS data, starting with mapped data from the sequence information generated by the sequencer to a molecular level understanding of the biology being studied.
"We are very pleased to add Genomatix advanced Next Generation Sequencing downstream analysis capabilities to our ongoing effort of providing our university-wide user base with quality tools for their data analysis", said Dr. Jim Cavalcoli, Director of the CCDU Bioinformatics Core of the Center for Computational Medicine and Biology at the University of Michigan. "We are constantly looking for tools that have both in-depth data analysis capabilities coupled to an intuitive user interface, which we found in the Genomatix Genome Analyzer. The fact that it provides command line access for our IT people was simply an added bonus."
Peter Grant, Chief Executive Officer at Genomatix, USA commented: "Placing our Genomatix Genome Analyzer at the University of Michigan in an environment providing campus-wide accessibility to our tools provides further validation of the quality and depth of the Genomatix' technology for the analysis of NGS data. That this represents our second installation at a university of such stature is a terrific vote of confidence not only for our existing technologies, but is also a strong endorsement of our abilities to keep up with the analysis demands of this very dynamic and rapidly growing technology. We have more than a decade of research and development behind many of the tools implemented in this sweeping array of analysis applications, and are prepared today for the data avalanche that will inevitably come from the 'next'-next generation of sequencers."
The Genomatix Genome Analyzer (GGA) delivers downstream software tools and databases for the deep biological analysis of mapped NGS data. It allows for easy integration and visualization in the extensive background annotation of our ElDorado genome database. The GGA extensively annotates genomic coordinates and surrounding areas derived from any mapping procedure. Clustering and peak finding, analysis for phylogenetic conservation, large scale correlation analysis with annotated genomic elements, meta-analysis of data correlation between different experiments, pathway mining for groups of identified genes, transcription factor binding site (TFBS) analysis (identification, over-representation, binding partner analysis, framework identification, phylogenetic conservation, regulatory SNP effects) and much more are all processes carried out on the GGA.
Genomatix Software GmbH is a computational biology company headquartered in Munich, Germany with a seat of business in Ann Arbor, MI, U.S.A. Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. Over a decade of developments in computational and systems biology has put Genomatix into position to have a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 180 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases.
March 26, 2009
MCTP bought Genomatix NextGen Sequencing Analysis Stations
Michigan Center for Translational Pathology uses Genomatix technology for data analysis of their in-house deep sequencing systems.
Munich (Germany), Ann Arbor, MI (USA) - March 26, 2009 - Genomatix Software, a leading provider of complete solutions for the analysis of Next Generation Sequencing (NGS) data, announced today that the Michigan Center for Translational Pathology (MCTP) at the University of Michigan installed a Genomatix Mining Station (GMS) and a Genomatix Genome Analyzer (GGA) at its labs in Ann Arbor, MI. GMS and GGA are a combination of purpose built high performance hardware and terabytes of proprietary database and software technology combined to provide a turnkey solution for the analysis of NGS data. Together they represent the only complete, integrated analysis solution for NGS data, starting with the raw data generated by the sequencer, leading to a molecular level understanding of the biology being studied.
Peter Grant, Chief Executive Officer at Genomatix, USA commented: "Placing our systems in these highly acclaimed labs at the University of Michigan makes us very proud, and confirms that Genomatix' technology is clearly at the leading edge of this important new genomic technology... right in step with the research that is being done here. We have more than a decade of research and development behind many of the tools implemented in this sweeping array of analysis applications, a fact that places us at the very forefront of the NGS data analysis market. We are prepared today for the data avalanche that will inevitably come from the 'next'-next generation of sequencers."
The MCTP was formed in 2005, under the directorship of Dr. Arul Chinnaiyan, M.D., Ph.D.and Howard Hughes Medical Investigator, as a focused initiative to bring research discoveries from molecular medicine to practical, clinical applications for the identification of biomarkers and therapeutic targets for cancers of the prostate, breast, lung, colon, and skin, as well as other diseases. MCTP utilizes innovative "omics" approaches, cutting-edge high-throughput genomic screening, along with novel bioinformatics and computational analysis to search the human genomes of patients for abnormalities. They comprehensively examine disease development from the foundations of genetic abnormality up through whole body systems, to gain a more integrated, complete insight into the origins of disease.
The Genomatix Mining Station is the first level analysis solution starting at the raw data from the sequencer, delivering ultra fast mapping, SNP detection, expression profiling and splice analysis. Copy number analysis, small RNA analysis and de-novo assembly are following shortly. Results seamlessly feed into second level analysis with the Genomatix Genome Analyzer which puts them into broad biological context, annotates, integrates and visualizes. Clustering, pattern detection, deep transcription factor analysis, phylogeny, correlation and meta-analysis, pathway and network mining are done by the GGA.
Genomatix Software GmbH is a computational biology company headquartered in Munich, Germany with a seat of business in Ann Arbor, MI, U.S.A. Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. Over a decade of developments in computational and systems biology has put Genomatix into position to have a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 180 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases.
March 12, 2009
Genomatix gets Patent for Comparative Genomics Method
Innovative approach allows for identification and assignment of functionally corresponding regulatory sequences throughout different eukaryotic genomes.
Munich (Germany), Ann Arbor, MI (USA) - March 12, 2009 - Genomatix Software, a company with an outstanding track record in the analysis of genomic data generated by high throughput technologies, announced today that it was issued patent No. EP 1 800 232 B1, “Identification and assignment of functionally corresponding regulatory sequences for orthologous loci in eukaryotic genomes” by the European Patent Office.
The patent relates to a sophisticated method for identification of networks of functionally related regulatory DNA sequences in different eukaryotic species. With today’s high throughput sequencing technology data from an increasing number of various organisms become available. However, the genomic sequence does not reveal scientific insight in the functional organization of the genome. For such the genome needs to be annotated (e.g. location of genes, promoters, genomic repeats etc.) Annotation of regulatory sequences like promoters and enhancers is a special challenge which is not satisfactory solved until today. The patent describes a method using a defined transcriptional start side from a well annotated genome (like human) as an anchor to identify corresponding regulatory regions in the orthologous areas of less defined species. Results have been proven to be of extremely high quality. Genomatix applies this method in its genomic database ElDorado since several years now and numerous such predicted promoters have been verified experimentally in the meantime.
Dr. Andreas Klingenhoff, Genomatix' Head of Genomics and Annotation and the inventor of the approach says: "We developed the method over several years, running many projects aimed to identify the evolutionary conserved regulatory elements shared between different eukaryotes. It was essential in understanding regulatory networks, mechanisms and pathways, including disease mechanisms in humans. With increasing insight into the extreme complexity of the transcriptome, the method becomes more and more valuable. We continuously work on further improvements and apply it to an increasing number of species, especially in light with our efforts in next generation sequencing data analysis."
Genomatix Software GmbH is a computational biology company headquartered in Munich, Germany with a seat of business in Ann Arbor, MI, U.S.A. Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. Over a decade of developments in computational and systems biology has put Genomatix into position to have a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 180 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases.
March 5, 2009
Genomatix Next Generation Sequencing analysis solution GGA installed at Barcelona Centre for Genomic Regulation
Munich, Germany and Barcelona, Spain
- March 5, 2009 - The Centre for Genomic Regulation (CRG) in Barcelona, Spain purchased the Genomatix Genome Analyzer (GGA), as announced today by Genomatix Software GmbH.
GGA comprises purpose built high performance hardware and terabytes of proprietary databases and software providing a complete solution for the analysis of Next Generation Sequencing (NGS) data after mapping to the genome.
"In regards to the machine, I love it! And I have advertised it to many colleagues," says Dr. Ramin Shiekhattar, Group Leader within the Gene Regulation Programme.
"We are pursuing research in two major areas. The first is the molecular mechanism of cancer. We are working to address the mechanism by which tumor suppressors such as BRCA1 and BRCA2 exerted their biological effects. Our second avenue of research entails the delineation of the mechanisms by which the genome is silenced through chromatin modification and small regulatory RNA. The laboratory's goal is to understand the epigenetic regulation of gene expression in mammalian development and genetic disease."
Klaus May, Chief Business Officer at Genomatix says: "I am extremely excited that one of our installations of the GGA went to the CRG in Barcelona. This is a very impressive institution with outstanding scientists and cutting edge equipment at a wonderful location. Our GGA definitely fits into that environment and will contribute substantially to the analysis of data produced by their sequencers."
The Genomatix Genome Analyzer (GGA) delivers all downstream tools and databases for deep biological analysis of mapped data coming from next generation sequencers. It allows for easy integration and visualization within the terabytes of background annotation of the most complete mammalian genome annotation: ElDorado. GGA delivers annotation of genomic coordinates from GMS or any other mapping procedure, clustering and peak finding, analysis for phylogenetic conservation, large scale correlation analysis with any annotated genomic elements, meta-analysis of data correlation between different experiments, pathway mining for groups of identified genes, transcription factor binding site (TFBS) analysis (identification, over-representation, binding partner analysis, framework identification, phylogenetic conservation, regulatory SNP effects) and much more.
The Centre for Genomic Regulation (CRG) is a basic biomedical research centre, created by initiative of the Department of Universities, Research and Information Society and the Department of Health of the Catalan Government, with the participation of the Pompeu Fabra University, and the Spanish Ministry of Education and Science. The objective of the CRG is to promote an excellent basic research in biomedicine and, particularly, in the genomic and proteomic fields.
Genomatix Software GmbH is a computational biology company headquartered in Munich, Germany with a seat of business in Ann Arbor, MI, U.S.A. Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. Over a decade of developments in computational and systems biology has put Genomatix into position to have a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 180 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases.
March 2, 2009
Boehringer Ingelheim uses Genomatix'
Next Generation Sequencing Data Analysis Systems
Boehringer Ingelheim chooses Genomatix technology for data analysis of their in-house deep sequencing systems.
Munich, Germany
- March 2, 2009 - Genomatix Software, a leading provider of complete solutions for the analysis of Next Generation Sequencing (NGS) data, announced today that Boehringer Ingelheim Pharma GmbH & Co. KG installed a Genomatix Mining Station (GMS) and a Genomatix Genome Analyzer (GGA) at its Pharma Research Center in Biberach, Germany. GMS and GGA are a combination of purpose built high performance hardware and terabytes of proprietary databases and software technology. Together they represent the only complete and integrated analysis solution for NGS data, from the raw data generated by the sequencer, to a molecular level understanding of the biology being studied.
Klaus May, Chief Business Officer at Genomatix says: "Adding the competent and well respected company Boehringer Ingelheim to our growing customer list for our NGS analysis systems makes us very proud. It confirms that Genomatix leading edge technology is going the right direction. More than a decade of research and development allows us to be at the forefront of the exciting NGS market. We are prepared today for the data avalanche to be expected from future generations of next generation sequencers."
The Genomatix Mining Station (GMS) is based on a proprietary genomic pattern recognition paradigm, or GenomeThesaurus, which allows for input of raw sequence reads plus optional quality files from any deep sequencing hardware. It provides ultra fast mapping of sequences of any length (starting from 8bp) with no practical limits on the number of point mutations and/or insertions and deletions that can be taken into account during the mapping process. Depending on the nature of the experiment, the GMS can provide SNP detection and genotyping, copy number analysis, and small RNA analysis. For ChIPseq data, the GMS delivers clustering and peak finding, and performs automated binding pattern identification. For RNAseq experiments, normalized expression values are calculated at the exon and transcript level. A special GenomeThesaurus is also provided for potential splice junctions, which allows for splice junction analysis and identification of new transcriptional units.
For genomic re-sequencing and newly sequenced genomes, a de novo assembly will be provided.
The Genomatix Genome Analyzer (GGA) delivers downstream software tools and databases for the deep biological analysis of data coming from the GMS. It allows for easy integration and visualization in the terabytes of background annotation of the ElDorado genome database. GGA extensively annotates genomic coordinates and surrounding areas derived by the GMS or any other mapping procedure. Clustering and peak finding, analysis for phylogenetic conservation, large scale correlation analysis with annotated genomic elements, meta-analysis of data correlation between different experiments, pathway mining for groups of identified genes, transcription factor binding site (TFBS) analysis ( identification, over-representation, binding partner analysis, framework identification, phylogenetic conservation, regulatory SNP effects) and much more are all processes carried out on the GGA.
Genomatix Software GmbH is a computational biology company headquartered in Munich, Germany with a seat of business in Ann Arbor, MI, U.S.A. Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. Over a decade of developments in computational and systems biology has put Genomatix into position to have a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 180 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases.
February 4, 2009
GeneCore Facility at the EMBL Purchases Genomatix'
Next Generation Sequencing Data Analysis Systems
Thorough tests with real life data let EMBL go for Genomatix
Munich, Germany and Heidelberg, Germany
- February 4, 2009 - Genomatix Software, a leading provider of complete solutions for the analysis of Next Generation Sequencing (NGS) data, announced today that the European Molecular Biology Laboratory (EMBL) installed a Genomatix Mining Station and a Genomatix Genome Analyzer at its Genomics Core Facility. These systems deliver the only complete and integrated analysis solution for NGS data, from the raw data generated by the sequencer, to a molecular level understanding of the biology being studied.
"Based on joint scientific approaches and collaborations, it is clear that we have a long term relationship with Genomatix. As such, we have received early access to their solution for NGS data analysis", says Dr. Vladimir Benes, Head of Genomics Core Facility at EMBL. "We did thorough tests with real life data sets and were impressed by the speed, ease of use and extended reach into the biology provided by their system. The amount of high quality data being produced at our core facility every day necessitates analysis pipelines that can keep pace."
Klaus May, Chief Business Officer at Genomatix says: "We are very pleased that the EMBL has chosen our GMS and GGA. With our combined hardware/software approach, we are prepared for the arrival of the data tsunami expected from Third Generation Sequencers and beyond. For EMBL, with brilliant scientists from all fields, ease of use was important so that the biologists can readily use the system through its easy to use graphical interface. The bio-informaticians were equally pleased to find that they could approach the extensive software and data content with command line access. "
The Genomatix Mining Station (GMS) is based on a proprietary genomic pattern recognition paradigm, or GenomeThesaurus, which allows for input of raw sequence reads plus optional quality files from any deep sequencing hardware. It provides ultra fast mapping of sequences of any length (starting from 8 bp) with no practical limits on the number of point mutations and/or insertions and deletions that can be taken into account during the mapping process. Depending on the nature of the experiment, the GMS can provide SNP detection and genotyping, copy number analysis, and small RNA analysis. For ChIP-Seq data, the GMS delivers clustering and peak finding, and performs automated binding pattern identification. For RNA-Seq experiments, normalized expression values are calculated at the exon and transcript level. A special GenomeThesaurus is also provided for potential splice junctions, which allows for splice junction analysis and identification of new transcriptional units.
For genomic re-sequencing and newly sequenced genomes, a de novo assembly will be provided.
The Genomatix Genome Analyzer (GGA) delivers downstream software tools and databases for the deep biological analysis of data coming from the GMS. It allows for easy integration and visualization in the terabytes of background annotation of the ElDorado genome database. GGA extensively annotates genomic coordinates and surrounding areas derived by the GMS or any other mapping procedure. Clustering and peak finding, analysis for phylogenetic conservation, large scale correlation analysis with annotated genomic elements, meta-analysis of data correlation between different experiments, pathway mining for groups of identified genes, transcription factor binding site (TFBS) analysis ( identification, over-representation, binding partner analysis, framework identification, phylogenetic conservation, regulatory SNP effects) and much more are all processes carried out on the GGA.
EMBL's Genomics Core Facility (GeneCore) is the in-house genomics service centre at EMBL equipped with state-of-the-art technologies required for functional genomics analyses and operated by highly-qualified staff. The focus is on the benefits and utilization of new technologies, which are also developed at EMBL, to improve the quality, efficiency and relevance of laboratory data.
Genomatix Software GmbH is a computational biology company headquartered in Munich, Germany with a seat of business in Ann Arbor, MI, U.S.A. Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. Over a decade of developments in computational and systems biology has put Genomatix into position to have a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 180 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases.
More information is available from http://www.genomatix.de or http://www.genomatix-software.com.
About EMBL
The European Molecular Biology Laboratory is a basic research institute funded by public research monies from 20 member states (Austria, Belgium, Croatia, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the United Kingdom) and associate member state Australia. Research at EMBL is conducted by approximately 80 independent groups covering the spectrum of molecular biology. The Laboratory has five units: the main Laboratory in Heidelberg, and Outstations in Hinxton (the European Bioinformatics Institute), Grenoble, Hamburg, and Monterotondo near Rome. The cornerstones of EMBL's mission are: to perform basic research in molecular biology; to train scientists, students and visitors at all levels; to offer vital services to scientists in the member states; to develop new instruments and methods in the life sciences and to actively engage in technology transfer activities. EMBL's International PhD Programme has a student body of about 170. The Laboratory also sponsors an active Science and Society programme. Visitors from the press and public are welcome.
January 28, 2009
Genomatix Joins Illumina-Connect Program
Munich, Germany and Ann Arbor, MI
- January 28, 2009 - Genomatix Software announced today that is has joined the Illumina-Connect program, linking them to the ongoing Illumina program and working with them to develop new tools and applications for Illumina-generated data.
Klaus May, Chief Business Officer for Genomatix Software in Munich, Germany commented: "As the industry's only provider of a complete NGS data analysis capability, we are extremely pleased to be part of Illumina's effort. The majority of our current customer base is generating their NGS data on Illumina machines, and as such we are very familiar with them". Peter Grant, Chief Executive Officer for Genomatix Software in Ann Arbor, Michigan, further commented "Working with Illumina generated NGS data has helped us greatly in our ongoing effort to refine and further expand our analysis capabilities in this very demanding market. Being a part of the Illumina-Connect program should help us to better focus those efforts as well as help us keep up with the rapidly expanding portfolio of Illumina NGS applications".
Besides the well established Genomatix micro array analysis pipeline which works with output from the Illumina BeadChip platform Genomatix delivers a complete solution for the analysis of Next Generation Sequencing (NGS) data. This combined software/hardware platform consists of two units: the Genomatix Mining Station (GMS) and the Genomatix Genome Analyzer (GGA).
The GMS is based on a proprietary genomic pattern recognition paradigm, or GenomeThesaurus, which allows for input of raw sequence reads plus optional quality files from any deep sequencing hardware, especially the Illumina Genome Analyzer. It provides ultra fast mapping of sequences of any length (starting from 8bp) with no practical limits on the number of point mutations and/or insertions and deletions that can be taken into account during the mapping process. Depending on the nature of the experiment, the GMS can provide SNP detection and genotyping, copy number analysis, and small RNA analysis. For ChIP-Seq data, the GMS delivers clustering and peak finding, and performs automated binding pattern identification. For RNA-Seq experiments, normalized expression values are calculated at the exon and transcript level. A special GenomeThesaurus is also provided for potential splice junctions, which allows for splice junction analysis and identification of new transcriptional units. For genomic re-sequencing and newly sequenced genomes, a de novo assembly will be provided.
The GGA delivers downstream software tools and databases for the deep biological analysis of genomic position data coming from the GMS or any other technology. It allows for easy integration and visualization in the terabytes of background annotation of the ElDorado genome database. GGA extensively annotates genomic coordinates and surrounding regions. Clustering and peak finding, analysis for phylogenetic conservation, large scale correlation analysis with annotated genomic elements, meta-analysis of data correlation between different experiments, pathway mining for groups of identified genes, transcription factor binding site (TFBS) analysis ( identification, over-representation, binding partner analysis, framework identification, phylogenetic conservation, regulatory SNP effects) and much more are all processes carried out on the GGA.
Genomatix Software GmbH is a computational biology company headquartered in Munich, Germany with a seat of business in Ann Arbor, MI, U.S.A. Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. Over a decade of developments in computational and systems biology has put Genomatix into position to have a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 180 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases.
More information is available from http://www.genomatix.de or http://www.genomatix-software.com. |
